DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that
stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying,
and reduces appetite and food intake. Therapeutic approaches for enhancing ... Cited by 403 - Related articles - All 10 versions
- ►glucagon.com [PDF] DJ Drucker - Gastroenterology, 2002 - Elsevier The glucagon-like peptides (GLP-1 and GLP-2) are proglucagon-derived peptides
cosecreted from gut endocrine cells in response to nutrient ingestion. GLP-1
acts as an incretin to lower blood glucose via stimulation of insulin ... Cited by 253 - Related articles - BL Direct - All 13 versions
LL Nielsen, AA Young, DG Parkes - Regulatory peptides, 2004 - Elsevier Exenatide (synthetic exendin-4), glucagon-like peptide-1 (GLP-1), and GLP-1
analogues have actions with the potential to significantly improve glycemic
control in patients with diabetes. Evidence suggests that these agents use ... Cited by 185 - Related articles - All 7 versions
- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion,
biological actions, and therapeutic relevance of the incretin peptides
glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ... Cited by 172 - Related articles - All 25 versions
- ►physiology.org JJ Holst - Physiological reviews, 2007 - Am Physiological Soc Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in
the intestinal epithelial endocrine L-cells by differential processing of
proglucagon, the gene which is expressed in these cells. The current ... Cited by 113 - Related articles - BL Direct - All 5 versions
- ►nih.gov F Preitner, M Ibberson, I Franklin, C Binnert, … - Journal of Clinical Investigation, 2004 - Am Soc Clin Investig The role of the gluco-incretin hormones GIP and GLP-1 in the control of β cell
function was studied by analyzing mice with inactivation of each of these
hormone receptor genes, or both. Our results demonstrate that glucose ... Cited by 94 - Related articles - BL Direct - All 10 versions
- ►endojournals.org BL Wajchenberg - Endocrine reviews, 2007 - Endocrine Soc There is a progressive deterioration in ß-cell function and mass in type 2
diabetics. It was found that islet function was about 50% of normal at the time
of diagnosis, and a reduction in ß-cell mass of about 60% was shown at ... Cited by 100 - Related articles - BL Direct - All 7 versions
- ►nih.gov C Knauf, PD Cani, C Perrin, MA Iglesias, JF … - Journal of Clinical Investigation, 2005 - Am Soc Clin Investig Intestinal glucagon-like peptide–1 (GLP-1) is a hormone released into the
hepatoportal circulation that stimulates pancreatic insulin secretion. GLP-1
also acts as a neuropeptide to control food intake and cardiovascular ... Cited by 82 - Related articles - BL Direct - All 12 versions
MC Riddle, DJ Drucker - Diabetes Care, 2006 - Am Diabetes Assoc Current therapies for type 2 diabetes are frequently associated with inadequate
control of postprandial hyperglycemia, weight gain, and, in the case of oral
agents, loss of efficacy over time. A better understanding of physiological ... Cited by 71 - Related articles - BL Direct - All 10 versions
J Sturis, CF Gotfredsen, J Rømer, B Rolin, … - British journal of pharmacology, 2003 - pubmedcentral.nih.gov When liraglutide was dosed sc at 150 μg kg −1 bid for 6 weeks in ZDF rats
6–8 weeks of age at study start, diabetes development was markedly attenuated.
Blood glucose was approximately 12 mM lower compared to vehicle (P<0.0002), ... Cited by 70 - Related articles - BL Direct - All 4 versions
